Tech Company Financing Transactions
Agennix Funding Round
Agennix, based in Princeton, received $22 million from BCM Technologies and private investors.
Transaction Overview
Company Name
Announced On
3/31/2005
Transaction Type
Venture Equity
Amount
$22,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
20 Fraunhoferstraße
Princeton, 82152
Germany
Princeton, 82152
Germany
Phone
Website
Email Address
Overview
Agennix AG is a publicly listed biopharmaceutical company. The Company's clinical development programs include oral talactoferrin alfa; a topical gel form of talactoferrin and RGB-286638, a multi-targeted kinase inhibitor. Agennix's registered seat is in Heidelberg, Germany. The Company's site of operation is in Princeton, New Jersey.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Financial Officer
Torsten Hombeck
Chief Medical Officer
Rajesh Malik
VP - Bus. Development
Colin Freund
VP - General Counsel
Brent Hatzis-Schoch
VP - Human Resources
Greg Hamm
VP - Regulatory Affairs
Christine Boisclair
Browse more venture capital transactions:
Prev: 3/31/2005: Vericept venture capital transaction
Next: 3/31/2005: RealManage venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs